What is the initial and intensive‑care unit (ICU) management of a patient with non‑ST‑segment elevation myocardial infarction (NSTEMI)?

Initial and ICU Management of NSTEMI

For patients with NSTEMI, immediate antiplatelet therapy with aspirin plus a P2Y12 inhibitor (preferably ticagrelor or prasugrel over clopidogrel) combined with anticoagulation should be initiated, followed by risk stratification to determine timing of invasive strategy and appropriate level of care—with ICU admission reserved for hemodynamically unstable patients or those at very high risk of complications rather than routine admission. 1

Initial Emergency Department Management

Immediate Assessment and Monitoring

• Obtain 12-lead ECG within 10 minutes of presentation to confirm NSTEMI (absence of ST-elevation but may show ST-depression, T-wave inversions, or be normal) 1
• Measure high-sensitivity cardiac troponin immediately, with repeat measurement at 1-2 hours if initial result is nondiagnostic 1
• Perform focused echocardiography to evaluate left ventricular function and rule out mechanical complications 1
• Continuous cardiac monitoring for arrhythmias 1

Antiplatelet Therapy (Dual Antiplatelet Therapy - DAPT)

Aspirin:

• Continue aspirin indefinitely at standard dosing 1

P2Y12 Inhibitor Selection (in order of preference):

• Ticagrelor (180 mg loading dose, 90 mg twice daily) is recommended for all moderate-to-high risk patients with elevated troponins, regardless of invasive vs. conservative strategy 1
• Prasugrel (60 mg loading dose, 10 mg daily) is recommended for patients proceeding to PCI who are not pretreated with clopidogrel 1
• Clopidogrel (300-600 mg loading dose, 75 mg daily) if ticagrelor or prasugrel contraindicated 1
• Continue P2Y12 inhibitor for 12 months unless excessive bleeding risk 1

Anticoagulation Therapy

For invasive strategy patients:

• Enoxaparin or fondaparinux is preferable to UFH unless CABG planned within 24 hours 1
• Continue anticoagulation until PCI, then discontinue for uncomplicated cases 1

For conservative strategy patients:

• Continue UFH for 48 hours OR enoxaparin/fondaparinux for duration of hospitalization up to 8 days 1

GP IIb/IIIa Inhibitors

• For invasive strategy: Consider adding eptifibatide or tirofiban upstream (before angiography) for troponin-positive high-risk patients 1
• For conservative strategy: May be reasonable to add eptifibatide or tirofiban for high-risk patients with recurrent ischemia despite medical therapy 1
• Abciximab should NOT be administered unless PCI is planned 1

Risk Stratification and Timing of Invasive Strategy

Very High-Risk Criteria (Immediate invasive strategy <2 hours):

• Hemodynamic instability or cardiogenic shock
• Recurrent or ongoing chest pain refractory to medical treatment
• Life-threatening arrhythmias or cardiac arrest
• Mechanical complications of MI
• Acute heart failure with refractory angina or ST-segment changes
• Recurrent dynamic ST- or T-wave changes, particularly with intermittent ST-elevation 1

High-Risk Criteria (Early invasive strategy <24 hours):

• Rise or fall in cardiac troponin compatible with MI
• Dynamic ST- or T-wave changes (symptomatic or silent)
• GRACE score >140 1

Intermediate-Risk Criteria (Invasive strategy <72 hours):

• Diabetes mellitus
• Renal insufficiency (eGFR <60 mL/min/1.73 m²)
• LVEF <40% or congestive heart failure
• Early post-infarction angina
• Recent PCI or prior CABG
• GRACE risk score 109-140
• Recurrent symptoms or ischemia on non-invasive testing 1

ICU Admission Decisions

ICU admission should NOT be routine for hemodynamically stable NSTEMI patients. 2, 3 The evidence demonstrates that routine ICU use for stable NSTEMI patients does not improve mortality, medication adherence, or readmission rates compared to general ward care. 2, 3

Indications for ICU Admission:

Admit to ICU only if:

• Hemodynamic instability (cardiogenic shock, hypotension)
• Cardiac arrest or life-threatening arrhythmias
• Respiratory failure requiring mechanical ventilation
• High-grade atrioventricular block
• Acute heart failure with hemodynamic compromise
• Ongoing refractory ischemia despite maximal medical therapy 1, 4

Risk Stratification for ICU Need:

The ACTION ICU risk score can identify patients requiring ICU-level care based on presentation variables 4, 5:

• Signs/symptoms of heart failure
• Initial heart rate and systolic blood pressure
• Initial troponin level
• Initial serum creatinine
• Prior revascularization
• Chronic lung disease
• ST-segment depression
• Age

Patients with ACTION ICU score <3 have very low risk (<4%) of complications requiring ICU care and can be safely managed on a monitored cardiac step-down unit or general ward with telemetry. 4, 5

Conservative Strategy Management (If No High-Risk Features)

Stress Testing:

• Perform stress test if no features necessitate angiography (recurrent symptoms, heart failure, serious arrhythmias) 1
• If stress test shows high risk → proceed to diagnostic angiography 1
• If stress test shows low risk → continue medical management 1

Medical Management for Low-Risk Patients:

• Continue aspirin indefinitely 1
• Continue P2Y12 inhibitor (clopidogrel or ticagrelor) for up to 12 months 1
• Discontinue IV GP IIb/IIIa inhibitor if started 1
• Continue anticoagulation as outlined above, then discontinue 1

Pre-Procedural Management for Planned Revascularization

For Planned PCI:

• Continue aspirin 1
• Administer P2Y12 inhibitor loading dose if not already given 1
• Discontinue anticoagulation after uncomplicated PCI 1

For Planned CABG:

• Continue aspirin 1
• Discontinue clopidogrel 5-7 days before elective CABG 1
• Discontinue prasugrel at least 7 days before CABG 1
• Discontinue ticagrelor at least 7 days before CABG 1
• Discontinue GP IIb/IIIa inhibitor 4 hours before CABG 1
• Discontinue enoxaparin 12-24 hours before CABG and transition to UFH 1
• Discontinue fondaparinux 24 hours before CABG and transition to UFH 1

Common Pitfalls to Avoid

• Do not routinely admit hemodynamically stable NSTEMI patients to ICU—this wastes resources without improving outcomes 2, 3
• Do not use fibrinolytic therapy in NSTEMI—it increases risk of MI without benefit 1
• Do not use abciximab unless PCI is planned 1
• Do not forget to hold P2Y12 inhibitors for appropriate duration before elective CABG to reduce bleeding risk 1
• Do not delay invasive strategy in very high-risk patients (hemodynamic instability, refractory ischemia, life-threatening arrhythmias) 1